Literature DB >> 3651795

The slow channel syndrome. Two new cases.

H J Oosterhuis1, J Newsom-Davis, J H Wokke, P C Molenaar, T V Weerden, B S Oen, F G Jennekens, H Veldman, A Vincent, D W Wray.   

Abstract

Two patients are described with a myasthenic syndrome that presented in early adult life. One patient had 2 asymptomatic first degree relatives with similar electrophysiological findings. Both patients had abnormal fatiguability, arm weakness being prominent; neither of them responded to anticholinesterase medication. An abnormal decrement at 3 Hz stimulation was present, and a single stimulus evoked a repetitive response. Electrophysiological studies on biopsied intercostal muscle showed miniature endplate potentials of normal amplitudes but with prolonged rise and decay times. Anticholinesterase staining (Case 1) was not reduced, and showed elongation of some endplates. Ultrastructural studies (Case 2) showed degeneration of junctional folds and diffusely thickened endplate basal lamina. Calcium deposits were not observed and myopathic changes were slight. The findings are consistent with a prolonged open time of the ACh-induced ion channel.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3651795     DOI: 10.1093/brain/110.4.1061

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  7 in total

1.  Calpain activation impairs neuromuscular transmission in a mouse model of the slow-channel myasthenic syndrome.

Authors:  Jason S Groshong; Melissa J Spencer; Bula J Bhattacharyya; Elena Kudryashova; Bhupinder P S Vohra; Roberto Zayas; Robert L Wollmann; Richard J Miller; Christopher M Gomez
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

2.  Slow-channel transgenic mice: a model of postsynaptic organellar degeneration at the neuromuscular junction.

Authors:  C M Gomez; R Maselli; J E Gundeck; M Chao; J W Day; S Tamamizu; J A Lasalde; M McNamee; R L Wollmann
Journal:  J Neurosci       Date:  1997-06-01       Impact factor: 6.167

3.  3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia.

Authors:  J Palace; C M Wiles; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-12       Impact factor: 10.154

4.  Pregnancy in congenital myasthenic syndrome.

Authors:  L Servais; H Baudoin; K Zehrouni; P Richard; D Sternberg; E Fournier; B Eymard; T Stojkovic
Journal:  J Neurol       Date:  2012-10-30       Impact factor: 4.849

5.  Properties of the human muscle nicotinic receptor, and of the slow-channel myasthenic syndrome mutant epsilonL221F, inferred from maximum likelihood fits.

Authors:  C J Hatton; C Shelley; M Brydson; D Beeson; D Colquhoun
Journal:  J Physiol       Date:  2003-01-24       Impact factor: 5.182

Review 6.  Decoding pathogenesis of slow-channel congenital myasthenic syndromes using recombinant expression and mice models.

Authors:  José David Otero-Cruz; Carlos Alberto Báez-Pagán; Luisamari Dorna-Pérez; Gary Emanuel Grajales-Reyes; Rosaura Teresa Ramírez-Ordoñez; Carlos A Luciano; Christopher Manuel Gómez; José Antonio Lasalde-Dominicci
Journal:  P R Health Sci J       Date:  2010-03       Impact factor: 0.705

Review 7.  Autoantibodies to neurotransmitter receptors and ion channels: from neuromuscular to neuropsychiatric disorders.

Authors:  Pilar Martinez-Martinez; Peter C Molenaar; Mario Losen; Jo Stevens; Marc H De Baets; Andrei Szoke; Jerome Honnorat; Ryad Tamouza; Marion Leboyer; Jim Van Os; Bart P F Rutten
Journal:  Front Genet       Date:  2013-09-20       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.